Elina Haavisto

Elina Haavisto holds a Masters in Biology from the University of Turku and has 10 years of clinical and industrial experience in oncolytic adenoviruses. First at University of Helsinki during the Advanced Therapy Access Program and then at Oncos Therapeutics Ltd. (currently Targovax ASA), she has gained a broad experience in CMC, regulatory and adenovirus GMP manufacturing. Before joining TILT in 2017, Elina worked as a Biosafety Manager at Targovax, managing the communication and documentation concerning genetically modified organisms in preclinical and clinical studies. At TILT, Elina is responsible for the management of the outsourced virus manufacturing, overseeing the preparation of regulatory documentation and management of the trial sites. Elina has gained experience at all levels of pharmaceutical product development, from basic research to clinical trials.